Registered title, quoted from ClinicalTrials.gov
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 17 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 17
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Guizhou Medical University贵州医科大学附属医院GuiyangHospital page
- Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
- Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page
- Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
- Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
- Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
- Study siteZhongda Hospital, Southeast University东南大学附属中大医院NanjingHospital page
- Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT04494503, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pregnancy test results of serum samples obtained within 14 days before the first study drug administration in fertile female subjects were negative; If the serum pregnancy test results obtained are> 7 days from the first administration, urine sample obtained before the first study dose of study drug must be negative.
Inclusion criterion 9
Prior history of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy within 24 months or autologous hematopoietic stem cell transplantation within 12 months.
Exclusion criterion 1
Monoclonal antibody therapy against CLL was adopted within 4 weeks prior to the first dose of the study drug.
Exclusion criterion 2
Received Bcl-2 inhibitor treatment.
Exclusion criterion 6
Pregnancy or lactation, or pregnancy is expected during the study period or within 3 months after the last administration of treatment.
Exclusion criterion 12
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1.
Inclusion criterion 4
Within 3 years before entering the study, the subject had a history of active malignant tumors other than CLL / SLL, except that:
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04494503, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
Subjects who meet each of the following inclusion criteria are eligible to participate in this study:
- Age ≥18 years old.
- Diagnosis as relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma according to the IWCLL NCI-WG guidelines revised in 2008.
- Through radiological assessment, subjects with a lymph node length ≥ 10 cm require prior approval from the sponsor before enrollment.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1.
- QTcF interval ≤450ms in males, and ≤470ms in females.
- Adequate bone marrow function independent of growth factor and transfusion.
- Adequate renal and liver function.
- Willingness by males, female patients of child bearing potential, and their partners to use contraception by effective methods throughout the treatment period and for at least three months following the last dose of study drug.
- Pregnancy test results of serum samples obtained within 14 days before the first study drug administration in fertile female subjects were negative; If the serum pregnancy test results obtained are> 7 days from the first administration, urine sample obtained before the first study dose of study drug must be negative.
- Male subjects must avoid sperm donation throughout the treatment period and for at least three months following the last dose of study drug.
- Ability to understand and willingness to sign a written informed consent form approved by EC committee (the consent form must be signed by the patient prior to any screening or study-specific procedures).
- Willingness and ability to comply with study procedures and follow-up examination.
Exclusion Criteria:
Patients who meet any of the following exclusion criteria are not to be enrolled in this study:
- Prior history of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy within 24 months or autologous hematopoietic stem cell transplantation within 12 months.
- Monoclonal antibody therapy against CLL was adopted within 4 weeks prior to the first dose of the study drug.
- Receive any of the following treatments within 14 days or 5x half-life before the first dose of study drug, or clinically significant adverse reactions / toxicities due to previous treatments have not recovered to ≤ Grade 1: Anti-tumor therapies include chemotherapy, radiotherapy, anti-tumor steroid treatment, anti-tumor Chinese medicine treatment; investigational treatment, including targeted small molecule drugs.
- Use the following drugs within 14 days before the first dose of study drug: moderately potent CYP3A inhibitors such as fluconazole, ketoconazole and clarithromycin; moderately potent CYP3A inducers such as rifampin, carbamazepine, phenytoin And St. John's wort.
- Failure to recover adequately, at the discretion of the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
- Received Bcl-2 inhibitor treatment.
- Invasive NHL transformation or central nervous system (CNS) involvement. has occurred.
- Cardiovascular disease of grade ≥2 (New York Heart Association Class).
- A significant history of renal, neurological, psychiatric, pulmonary, endocrine, metabolic, immune, cardiovascular or liver disease. The investigator believes that participating in this study will have an adverse effect on him / her. For subjects requiring intervention for any of the above diseases in the past 6 months, the investigator and the sponsor must discuss.
- Warfarin or other anticoagulants is required.
- Known to be allergic to study drug ingredients or their analogues.
- Pregnancy or lactation, or pregnancy is expected during the study period or within 3 months after the last administration of treatment.
- Within 3 years before entering the study, the subject had a history of active malignant tumors other than CLL / SLL, except that:
- Fully treated cervical carcinoma in situ;
- Completely resected basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
- confinement and resection of previously cured malignancies (or other treatment).
- Has malabsorption syndrome or other conditions that are not suitable for enteral administration.
- Uncontrolled other clinically significant symptoms, including but not limited to: uncontrolled systemic infections (viruses, bacteria, or fungi), including but not limited to known hepatitis B virus (HBV) surface antigens and DNA positive(HBV-DNA≥2000copies/mL or ≥500IU/mL); Hepatitis C virus (HCV) antibody positive or RNA positive; human immunodeficiency virus (HIV) antibody positive; Febrile neutropenia occured within 1 week before administration.
- Primary active autoimmune diseases and connective tissue diseases, such as active and uncontrolled primary autoimmune hemocytopenia, including autoimmune hemolytic anemia (AIHA) and primary immune thrombocytopenia (ITP).
- Any other condition or circumstance that would, at the discretion of the investigator, make the patient unsuitable for participation in the study.
Quoted from ClinicalTrials.gov, NCT04494503, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT04494503, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.